EP 1320621 A2 20030625 - ENHANCED FIRST GENERATION ADENOVIRUS VACCINES EXPRESSING CODON OPTIMIZED HIV1-GAG, POL, NEF AND MODIFICATIONS
Title (en)
ENHANCED FIRST GENERATION ADENOVIRUS VACCINES EXPRESSING CODON OPTIMIZED HIV1-GAG, POL, NEF AND MODIFICATIONS
Title (de)
VERBESSERTE ADENOVIRALE VAKZINE DER ERSTEN GENERATION ZUR EXPRESSION CODON-OPTIMIERTEN HIV1-GAG, POL, NEF UND MODIFIKATIONEN(25.03.02)
Title (fr)
VACCINS ADENOVIRAUX DE PREMIERE GENERATION EVOLUES, EXPRIMANT LES PROTEINES GAG, POL ET NEF DU VIH-1 A OPTIMISATION DES CODONS ET LEURS MODIFICATIONS
Publication
Application
Priority
- US 0128861 W 20010914
- US 23318000 P 20000915
Abstract (en)
[origin: WO0222080A2] First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1- Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
IPC 1-7
IPC 8 full level
C12N 15/09 (2006.01); A61K 35/76 (2006.01); A61K 38/00 (2006.01); A61K 39/235 (2006.01); A61K 48/00 (2006.01); A61P 31/18 (2006.01); A61P 37/04 (2006.01); C07K 14/16 (2006.01); C12N 5/10 (2006.01); C12N 7/00 (2006.01); C12N 7/02 (2006.01); C12N 15/861 (2006.01); A61K 39/00 (2006.01); C12R 1/93 (2006.01)
CPC (source: EP)
A61P 31/18 (2017.12); A61P 37/04 (2017.12); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/53 (2013.01); A61K 2039/545 (2013.01); A61K 2039/57 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/10351 (2013.01); C12N 2740/16134 (2013.01); C12N 2740/16334 (2013.01); C12N 2830/42 (2013.01)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0222080 A2 20020321; WO 0222080 A3 20020502; WO 0222080 A8 20030116; WO 0222080 A9 20030306; AU 2001294562 B2 20070524; AU 2001294562 B8 20020326; AU 9456201 A 20020326; CA 2422882 A1 20020321; EP 1320621 A2 20030625; EP 1320621 A4 20051123; JP 2004508064 A 20040318
DOCDB simple family (application)
US 0128861 W 20010914; AU 2001294562 A 20010914; AU 9456201 A 20010914; CA 2422882 A 20010914; EP 01975214 A 20010914; JP 2002526335 A 20010914